Organon & Co. (OGN) Restructures, Expands in Women’s Health and Biosimilars

We recently published 10 Most Undervalued Pharma Stocks To Buy Now. Organon & Co stands tenth on our list and has expanded in women’s health and biosimilars.

Organon & Co. (NYSE:OGN), a global healthcare company specializing in women’s health, biosimilars, and established brands, underwent major changes in 2025. On May 1, the company slashed its quarterly dividend from $0.28 to $0.02 per share (annualized from $1.12 to $0.08) to prioritize debt reduction following its $1.2 billion acquisition of Dermavant in late 2024. This shift led to a 27% drop in stock price and a shareholder lawsuit alleging securities fraud due to prior reassurances about maintaining the dividend.

In April, Organon & Co. (NYSE:OGN) laid off 93 employees at its Jersey City headquarters, part of an ongoing global restructuring that began in 2023 and impacted around 5% of the workforce in early 2025. The restructuring responds partly to the loss of exclusivity for Atozet, the company’s second-largest product, which saw sales drop 9% in 2024, with continued decline expected.

Organon & Co. (OGN) Restructures, Expands in Women’s Health and Biosimilars

A robotic arm picking up a product assembly line, displaying the company’s consumer healthcare and wellness offerings.

That same month, the corporation acquired U.S. commercial rights to TOFIDENCE, a biosimilar to ACTEMRA (tocilizumab), from Biogen, expanding its immunology biosimilars portfolio. Organon & Co. (NYSE:OGN) will pay upfront fees, royalties, and milestone payments, while Bio-Thera Solutions retains U.S. manufacturing rights. TOFIDENCE enters a competitive space alongside Celltrion’s Avtozma and Fresenius Kabi’s Tyenne.

On June 12, the business partnered with Evvy to increase access to XACIATO (clindamycin phosphate) vaginal gel 2%, reaffirming its women’s health focus. Its flagship product, Nexplanon, posted 14% growth last quarter.

In leadership news, Ramona A. Sequeira, President at Takeda, will join the company’s Board on July 1, serving on the Talent Committee, as the company continues its strategic transformation.

While we acknowledge the risk and potential of OGN  as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than OGN and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None.